Abstract
To compare the cost-effectiveness of the two tyrosine kinase inhibitors (TKI), imatinib and dasatinib, in treating pediatric patients with philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) in China.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
